Sarcoma News

Soft tissue sarcoma is a rare type of cancer that affects the body’s soft tissues, such as muscles, fat and ligaments. There are more than 50 types of soft tissue sarcoma, including synovial sarcoma, which accounts for 5% to 10% of all soft tissue tumors diagnosed each year.

Phase 1, interventional, open-label study to determine the largest safe dose of chimeric T cells for patients with sarcoma, and to determine the safety of providing HER2-CD28 T cells after lymphodepleting chemotherapy.

NATIONAL HARBOR, Md. — An investigational anti-CD73 antibody appeared safe and demonstrated promising antitumor activity among patients with advanced cancers, according to phase 1/1b trial data presented at Society for Immunotherapy of Cancer Annual Meeting.

The FDA office that reviews applications for cancer therapies has been renamed and reorganized.

Uncontained power morcellation appeared associated with increased risk for mortality among women with occult uterine sarcoma, according to study results published in Journal of Clinical Oncology.

A 75-year-old woman with a medical history significant for obesity, diabetes mellitus type 2 and coronary artery disease presented with a 6-month history of constitutional symptoms, multiple hospitalizations for dehydration and electrolyte imbalances, and a precipitous functional decline. She was noted on several occasions to have a marked leukocytosis and was treated with various antibiotic regimens without a known infectious source. A CT scan of the chest/abdomen/pelvis revealed what was thought to be an enlarged inguinal lymph node (Figure 1).

The FDA has granted orphan drug designation to ADP-A2M4, an investigational specific peptide-enhanced affinity receptor T-cell therapy, for the treatment of soft tissue sarcomas.

BARCELONA — The International Association for the Study of Lung Cancer, or IASLC, today issued a declaration at its World Conference on Lung Cancer advising all physicians to screen their patients with cancer for tobacco use and recommend tobacco cessation.

The FDA announced today approved pexidartinib for the treatment of adults with symptomatic tenosynovial giant cell tumor that is linked to functional limitations or severe morbidity and does not improve with surgery.

The FDA granted priority review to tazemetostat for the treatment of patients with metastatic or locally advanced epithelioid sarcoma who are not eligible for curative surgery.